Amgen Raises Outlook After 3Q Profit, Sales Rise

What happened

Amgen raised its full-year revenue outlook to $38.9 billion–$39.7 billion from $38.2 billion–$39.4 billion and lifted adjusted earnings-per-share guidance to $22.90–$23.70. Third-quarter revenue rose 8% to $10.37 billion, while profit increased to $3.86 billion; adjusted earnings per share were $6.45.

Confirmed

Global impact / market context

Higher sales and profit, alongside increased full-year guidance, indicate stronger results than Amgen had previously expected. Product sales grew 8% on volume growth, with Repatha and Evenity among the reported growth drivers, but biosimilar drugs reduced revenue for certain products, creating an offset to that momentum.

Analyst inference

The quarter’s revenue and adjusted earnings per share exceeded FactSet analyst estimates, while the company also raised its yearly targets. That combination can shape investor expectations for future sales and earnings, but the article provides no share-price response or detail on the size of biosimilar-related pressure.

Analyst inference

What to watch

1. Check whether Amgen’s later results support its higher revenue range of $38.9 billion–$39.7 billion and adjusted earnings-per-share range of $22.90–$23.70. Analyst inference
2. Watch Repatha and Evenity sales for evidence that reported volume growth continues; the article gives their latest growth rates but no outlook for future demand. Analyst inference
3. Track the revenue effect of biosimilar drugs on the products they compete with, since the article says they cut into sales but gives no amounts. Analyst inference

Evidence

• Original source link unavailable